Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres

Bone Marrow Transplant. 2021 Mar;56(3):738-740. doi: 10.1038/s41409-020-01086-9. Epub 2020 Oct 19.

Authors

Georgia J McCaughan^{1

2}, Anvita Verma^{3

4}, Silvia Ling^{3

4}, Orly Lavee⁵, John J Moore^{5

4}, Adam Bryant^{3

4}

Affiliations

¹ Department of Haematology, St Vincent's Hospital, Sydney, NSW, Australia. Georgia.mccaughan@svha.org.au.
² Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia. Georgia.mccaughan@svha.org.au.
³ Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
⁴ Department of Haematology, Liverpool Hospital, Sydney, NSW, Australia.
⁵ Department of Haematology, St Vincent's Hospital, Sydney, NSW, Australia.

PMID: 33077903
DOI: 10.1038/s41409-020-01086-9

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Bortezomib / therapeutic use
Cyclophosphamide / therapeutic use
Dexamethasone / therapeutic use
Humans
Multiple Myeloma* / drug therapy

Substances

Bortezomib
Dexamethasone
Cyclophosphamide